What is claimed is:

1. A preparation formulation suitable for coating a transdermal patch wherein said preparation formulation comprises abaloparatide and an excipient comprising $ZnCl_2$.

2. A transdermal patch comprising a plurality of microprojections wherein at least one microprojection in the array is covered at least in part by a coating, said coating comprising abaloparatide and an excipient comprising $ZnCl_2$.

3. The transdermal patch of claim 2, wherein the microprojections are microneedles.

4. The preparation formulation of claim 1 or the transdermal patch according to claim 2 wherein:
the molar ratio of said excipient to abaloparatide is about 2.0.

5. The transdermal patch according to claim 2 or claim 4 wherein said abaloparatide is present on said array in an amount between 90-110 µg, 140-160 µg, 185-220 µg, 225-275 µg or about 100 µg, about 150 µg, about 200 µg, about 250 µg or about 300 µg.

6. A transdermal patch according to claim 4 or claim 5 for use in treating a condition selected from the group consisting of osteoporosis, osteopenia, osteoarthritis, and bone fracture in a subject.

7. A transdermal patch according to claim 4 or claim 5 for use in preventing vertebral, non-vertebral, clinical and major osteoporotic fractures.

8. A transdermal patch according to claim 4 or claim5 for use in improving bone mineral density (BMD), improving trabecular bone score (TBS), and/or reducing bone fractures in a subject.

9. The transdermal patch for use according to any one of claims 6-8 wherein:

(i) said patch comprises between 300-750 microprojections;

(ii) said administration comprises application of a force to the transdermal patch sufficient to drive one or more of the microprojections through the stratum comeum of the patient; and/or

(iii) the site of administration is the abdomen or the thigh.

10. The transdermal patch according to claim 4 wherein the patch comprises between 5 to 7% by weight of $ZnCl_2$.

11. The transdermal patch for use according to claim 9 wherein the patch remains at the site of administration for a period of time from 1 to 5 minutes, or from 5 to 10 minutes.

12. The transdermal patch according to any one of claims 2-5 or claim 10, comprising about 300 µg of abaloparatide.

13. The transdermal patch for use according to any one of claims 6-9 or claim 11, wherein the patch comprises about 300 µg of abaloparatide.